Vitamin D and Secondary Hyperparathyroidism in Chronic Kidney Disease: A Critical Appraisal of the Past, Present, and the Future

Overview

Journal Nutrients

Date 2022 Jul 27

PMID 35893866

Authors

Vincent Brandenburg

Markus Ketteler

Affiliations

Soon will be listed here.

Abstract

The association between vitamin D deficiency and especially critical shortage of active vitamin D (1,25-dihydroxyvitamin D, calcitriol) with the development of secondary hyperparathyroidism (sHPT) is a well-known fact in patients with chronic kidney disease (CKD). The association between sHPT and important clinical outcomes, such as kidney disease progression, fractures, cardiovascular events, and mortality, has turned the prevention and the control of HPT into a core issue of patients with CKD and on dialysis. However, vitamin D therapy entails the risk of unwanted side effects, such as hypercalcemia and hyperphosphatemia. This review summarizes the developments of vitamin D therapies in CKD patients of the last decades, from calcitriol substitution to extended-release calcifediol. In view of the study situation for vitamin D insufficiency and sHPT in CKD patients, we conclude that the nephrology community has to solve three core issues: (1) What is the optimal parathyroid hormone (PTH) target level for CKD and dialysis patients? (2) What is the optimal vitamin D level to support optimal PTH titration? (3) How can sHPT treatment support reduction in the occurrence of hard renal and cardiovascular events in CKD and dialysis patients?

Citing Articles

Hemodialysis Patients May Benefit from Cholecalciferol Treatment Targeting High Level of 25(OH)D.

Tarasewicz A, Dabrowska M, Komorniczak M, Zakrzewska A, Biedunkiewicz B, Malgorzewicz S Medicina (Kaunas). 2024; 60(11).

PMID: 39597015 PMC: 11596388. DOI: 10.3390/medicina60111831.

Nutrition support for patients with renal dysfunction in the intensive care unit: A narrative review.

Otis J, Parker N, Busch R Nutr Clin Pract. 2024; 40(1):35-53.

PMID: 39446967 PMC: 11713211. DOI: 10.1002/ncp.11231.

Identification of crucial genes and possible molecular pathways associated with active vitamin D intervention in diabetic kidney disease.

Zhang M, Tao M, Cao Q, Cai Y, Ding L, Li Z Heliyon. 2024; 10(19):e38334.

PMID: 39398062 PMC: 11470520. DOI: 10.1016/j.heliyon.2024.e38334.

Chest X-ray Findings and Prognostic Factors in Survival Analysis in Peritoneal Dialysis and Hemodialysis Patients: A Retrospective Cross-Sectional Study.

Tabakoglu N, Hatipoglu O Medicina (Kaunas). 2024; 60(8).

PMID: 39202612 PMC: 11356292. DOI: 10.3390/medicina60081331.

Association between dietary intake of selenium and chronic kidney disease in US adults: a cross-sectional study of NHANES 2015-2018.

Pi Y, Liao X, Song X, Cao Y, Tang X, Lin G Front Nutr. 2024; 11:1396470.

PMID: 39193560 PMC: 11347418. DOI: 10.3389/fnut.2024.1396470.

References

Gois P, Wolley M, Ranganathan D, Seguro A . Vitamin D Deficiency in Chronic Kidney Disease: Recent Evidence and Controversies. Int J Environ Res Public Health. 2018; 15(8). PMC: 6121405. DOI: 10.3390/ijerph15081773. View

Bover J, Gunnarsson J, Csomor P, Kaiser E, Cianciolo G, Lauppe R . Impact of nutritional vitamin D supplementation on parathyroid hormone and 25-hydroxyvitamin D levels in non-dialysis chronic kidney disease: a meta-analysis. Clin Kidney J. 2021; 14(10):2177-2186. PMC: 8483691. DOI: 10.1093/ckj/sfab035. View

Ketteler M, Rothe H, Kruger T, Biggar P, Schlieper G . Mechanisms and treatment of extraosseous calcification in chronic kidney disease. Nat Rev Nephrol. 2011; 7(9):509-16. DOI: 10.1038/nrneph.2011.91. View

Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H . Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA. 2012; 307(7):674-84. DOI: 10.1001/jama.2012.120. View

Maxwell D, Benjamin D, Donahay S, Allen M, HAMBURGER R, Luft F . Calcitriol in dialysis patients. Clin Pharmacol Ther. 1978; 23(5):515-9. DOI: 10.1002/cpt1978235515. View

Brandenburg V, Floege J . Adynamic bone disease-bone and beyond. NDT Plus. 2015; 1(3):135-47. PMC: 4421169. DOI: 10.1093/ndtplus/sfn040. View

Levey A, Eckardt K, Dorman N, Christiansen S, Hoorn E, Ingelfinger J . Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Kidney Int. 2020; 97(6):1117-1129. DOI: 10.1016/j.kint.2020.02.010. View

Zhou S, Glowacki J . Chronic kidney disease and vitamin D metabolism in human bone marrow-derived MSCs. Ann N Y Acad Sci. 2017; 1402(1):43-55. PMC: 5659722. DOI: 10.1111/nyas.13464. View

Agarwal R, Georgianos P . Con: Nutritional vitamin D replacement in chronic kidney disease and end-stage renal disease. Nephrol Dial Transplant. 2016; 31(5):706-13. DOI: 10.1093/ndt/gfw080. View

10.

Cunningham J, Locatelli F, Rodriguez M . Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol. 2011; 6(4):913-21. DOI: 10.2215/CJN.06040710. View

11.

Naylor K, McArthur E, Leslie W, Fraser L, Jamal S, Cadarette S . The three-year incidence of fracture in chronic kidney disease. Kidney Int. 2014; 86(4):810-8. DOI: 10.1038/ki.2013.547. View

12.

Nigwekar S, Bhan I, Thadhani R . Ergocalciferol and cholecalciferol in CKD. Am J Kidney Dis. 2012; 60(1):139-56. DOI: 10.1053/j.ajkd.2011.12.035. View

13.

Isakova T, Xie H, Yang W, Xie D, Anderson A, Scialla J . Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011; 305(23):2432-9. PMC: 3124770. DOI: 10.1001/jama.2011.826. View

14.

Isakova T, Cai X, Lee J, Mehta R, Zhang X, Yang W . Longitudinal Evolution of Markers of Mineral Metabolism in Patients With CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 2019; 75(2):235-244. PMC: 7012684. DOI: 10.1053/j.ajkd.2019.07.022. View

15.

Heerspink H, Stefansson B, Correa-Rotter R, Chertow G, Greene T, Hou F . Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020; 383(15):1436-1446. DOI: 10.1056/NEJMoa2024816. View

16.

Kalantar-Zadeh K, Kovesdy C . Clinical outcomes with active versus nutritional vitamin D compounds in chronic kidney disease. Clin J Am Soc Nephrol. 2009; 4(9):1529-39. DOI: 10.2215/CJN.02140309. View

17.

Wolisi G, Moe S . The role of vitamin D in vascular calcification in chronic kidney disease. Semin Dial. 2005; 18(4):307-14. DOI: 10.1111/j.1525-139X.2005.18407.x. View

18.

Bordier P, Marie P, Arnaud C . Evolution of renal osteodystrophy: correlation of bone histomorphometry and serum mineral and immunoreactive parathyroid hormone values before and after treatment with calcium carbonate or 25-hydroxycholecalciferol. Kidney Int Suppl. 1975; (2):102-12. View

19.

Nigwekar S, Tamez H, Thadhani R . Vitamin D and chronic kidney disease-mineral bone disease (CKD-MBD). Bonekey Rep. 2014; 3:498. PMC: 3944129. DOI: 10.1038/bonekey.2013.232. View

20.

Pimentel A, Urena-Torres P, Bover J, Fernandez-Martin J, Cohen-Solal M . Bone Fragility Fractures in CKD Patients. Calcif Tissue Int. 2020; 108(4):539-550. PMC: 8052229. DOI: 10.1007/s00223-020-00779-z. View